Who Supplies Meropenem to India from BELGIUM

To import finished pharmaceutical formulations containing Meropenem into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form 40 or 41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process includes providing stability data as per ICH guidelines for Zone IV, ensuring compliance with the Indian Pharmacopoeia standards. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews.

Imported Meropenem formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate product integrity under Indian climatic conditions. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in shipment delays, rejections, or destruction of the goods.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Meropenem. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in import dependency. Bilateral agreements between India and Belgium have facilitated smoother trade relations, but they have also introduced additional compliance requirements to ensure product quality and safety.

India imports finished Meropenem formulations primarily due to the need for patented or branded products not available domestically, specific dosage forms, and the inability of local manufacturers to meet certain quality standards. The market size for Meropenem in India is substantial, with imports accounting for a significant portion of the total demand. The reliance on imports is driven by the complexity of manufacturing Meropenem formulations and the stringent quality requirements imposed by Indian regulatory authorities.

The Basic Customs Duty (BCD) for Meropenem formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable at 12%, calculated on the sum of the CIF (Cost, Insurance, and Freight) value plus the total duty. There are no exemptions or concessional rates for imports from Belgium.

Belgium's pharmaceutical industry is renowned for its high-quality standards and innovative formulations, making it a preferred source for Meropenem formulations in India. Belgium's adherence to international quality standards and its established reputation in the pharmaceutical sector provide a competitive advantage over other suppliers. While countries like China, Germany, and the United States also export Meropenem formulations to India, Belgium's consistent quality and reliability make it a favored choice among Indian importers.

India imports Meropenem formulations from Belgium due to the high quality and reliability of Belgian pharmaceutical products. Belgium offers patented formulations and specialized dosage forms that are not available domestically. The advanced technology and stringent quality control measures employed by Belgian manufacturers ensure that the products meet international standards, making them a preferred choice for Indian importers.

Compared to other origins like China, Germany, and the United States, Belgium offers a unique combination of quality, innovation, and regulatory compliance. While China may offer lower prices, the quality and regulatory standards may not always align with Indian requirements. Germany and the United States provide high-quality products but may have higher costs and longer lead times. Belgium's competitive pricing, coupled with its adherence to international quality standards, positions it favorably in the Indian market.

To optimize procurement of Meropenem formulations from Belgium, Indian buyers should consider the following actionable points:

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with demand forecasts to optimize costs.
5. 5Supplier Qualification: Conduct regular audits and assessments to ensure supplier compliance with quality and regulatory standards.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 to CDSCO for product registration.
3. 3Drug Import License: Apply for a license to import drugs from the DGFT